Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.

Kidney international - 1 Aug 2006

Huang Y, Border W A, Lawrence D A, Noble N A

Abstract excerpt

Plasminogen activator inhibitor-type 1 (PAI-1) is thought to be profibrotic by inhibiting plasmin generation, thereby decreasing turnover of pathological extracellular matrix (ECM). A mutant, noninhibitory PAI-1 (PAI-1R) was recently shown by us to increase glomerular plasmin generation and reduc...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Collagen Type I
Share to Fibrinolysin
Share to Fibronectins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glomerulonephritis

Share to Plasminogen

Share to Plasminogen Activator Inhibitor 1

Share to Proteinuria

Share to Tritium

Source

Identifiers

PMID: 16788698
DOI: 10.1038/sj.ki.5000353

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16788698-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.PMID 16788698Read ↗

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.Semantic proximity Read ↗

Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.Semantic proximity Read ↗

Renal fibrosis: not just PAI-1 in the sky.Semantic proximity Read ↗

What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?Semantic proximity Read ↗

Structure and function of the plasminogen/plasmin system.Semantic proximity Read ↗

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.Semantic proximity Read ↗

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.Semantic proximity Read ↗

A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.Semantic proximity Read ↗

Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression.Semantic proximity Read ↗

The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.Semantic proximity Read ↗

Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.Semantic proximity Read ↗

Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.